Target intelligence / Profile preview

Hepatitis A virus (HAV) (HAV)

Target
HAV
Molecular classification
Virus, Picornaviridae
01

Overview

Hepatitis A virus (HAV) is a non-enveloped, positive-sense RNA virus belonging to the Picornaviridae family and is the causative agent of hepatitis A, an acute inflammatory liver disease (StatPearls, 2023). The virus is primarily transmitted through the fecal-oral route, leading to symptoms such as jaundice, fever, and abdominal pain (WHO, 2023). Inactivated Hepatitis A viral antigens serve as the target for prophylactic vaccines, which are designed to elicit a robust and long-lasting immune response (CDC, 2023). Upon administration, these antigens are processed by the host's immune system to generate neutralizing antibodies that specifically target the viral capsid, preventing the virus from infecting hepatocytes (PubMed, PMID: 10843387). This mechanism of action provides effective protection against subsequent exposure to the wild-type virus. The use of these antigens in global vaccination programs has significantly reduced the incidence of HAV-related morbidity and mortality (NIH, 2022).

Other names
HAVHepatitis A virusInfectious hepatitis virusEnterovirus 72
02

Mechanism of action

Induction of active immunity through the production of neutralizing IgG antibodies against the Hepatitis A virus capsid.

03

Biological functions

Viral entryViral replicationImmune response induction
04

Disease associations

Hepatitis AInfectionLiver disease
05

Safety considerations

Injection site reactionFeverMalaiseAnaphylaxisHypersensitivity to vaccine components
06

Interacting drugs

Havrix

4 more in the full profile.

07

Biomarkers

Anti-HAV IgGAnti-HAV IgMAlanine aminotransferase (ALT)

Beyond the preview

Go deeper on Hepatitis A virus (HAV) (HAV).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatitis A virus (HAV) (HAV).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call